drugset
drugset / Trial / NCT02477449

Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers

NCT02477449 ↗

Phase 1 Completed 32 enrolled Lee's Pharmaceutical Limited CVie Therapeutics Co. Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Phase 1 study to investigate safety of istaroxime in healthy chinese volunteers.

Timeline

Start
2015-03
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Istaroxime Small molecule 0.25 ug/kg —
Subject Istaroxime Small molecule 0.5 ug/kg —
Subject Istaroxime Small molecule 1 ug/kg —

Indications

No indication recorded.